denkapparat Operations GmbH Increases Holdings in Insulet Corporation $PODD

Posted by on Sep 4th, 2026

denkapparat Operations GmbH increased its holdings in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 310.1% in the second quarter, Holdings Channel reports. The firm owned 9,104 shares of the medical instruments supplier’s stock after acquiring an additional 6,884 shares during the period. denkapparat Operations GmbH’s holdings in Insulet were worth $1,386,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Insulet during the second quarter worth about $1,018,582,000. State Street Corp grew its stake in shares of Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after buying an additional 65,317 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period.

Insulet Stock Performance

Shares of PODD stock opened at $150.58 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company’s 50-day simple moving average is $154.66 and its 200-day simple moving average is $177.94. The stock has a market capitalization of $10.44 billion, a price-to-earnings ratio of 28.15, a PEG ratio of 1.17 and a beta of 1.08.

Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same period in the previous year, the company earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Weiss Ratings lowered shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. William Blair started coverage on shares of Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating on the stock. Jefferies Financial Group decreased their target price on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Finally, Bank of America lowered their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $195.40.

Check Out Our Latest Analysis on PODD

Insulet Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Featured Articles

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.